Patents Assigned to Inserm
  • Xanthine derivative inhibitors of BET proteins
    Patent number: 11225481
    Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 18, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Xavier Morelli, Sébastien Combes, Jean-Claude Guillemot, Stéphanie Betzi, Yves Collette, Philippe Roche, Adrien Lugari, Sabine Milhas, Brigitt Raux, Iuliia Voitovich
  • Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
    Patent number: 11226343
    Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 18, 2022
    Assignees: BIOTHELIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LE RECHERCHE MEDICAL), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE DE LILLE
    Inventors: Philippe Lasalle, Sidney Chocron, Nathalie De Freitas Caires
  • METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS
    Publication number: 20220011217
    Abstract: A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.
    Type: Application
    Filed: November 29, 2019
    Publication date: January 13, 2022
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS EST CRÉTEIL VAL DE MARNE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Laurent KIGER, Pablo BARTOLUCCI, Michael MARDEN
  • Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof
    Patent number: 11219638
    Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 11, 2022
    Assignees: INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER), UNIVERSITE DE NANTES, INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Sylvia Colliec-Jouault, Corinne Sinquin, Jacqueline Ratiskol, Dominique Heymann, Carmen Ruiz-Velasco, Julie Chesneau
  • Methods and compositions for treating and preventing HIV
    Patent number: 11219683
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 11, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTE
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • HAFNIA ALVEI FORMULATIONS
    Publication number: 20210401020
    Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.
    Type: Application
    Filed: November 28, 2019
    Publication date: December 30, 2021
    Applicants: TARGEDYS, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Clémentine PICOLO, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
  • METHOD AND DEVICE FOR DETERMINING A FLOW RATE AND/OR A CONCENTRATION OF PARTICLES OF A FLUID
    Publication number: 20210396559
    Abstract: A method for determining a flow rate and/or a concentration of particles of a fluid flowing in a chamber, which includes the steps of: producing an ultrasound beam of a given frequency with a first transducer such that all fluid components traveling through an intersection region between the ultrasound beam and the chamber are insonated by the first transducer; receiving Doppler-shifted ultrasound signals generated by the fluid components in the insonated region of the chamber with a second transducer; acquiring the ultrasound signals received by the second transducer during an acquisition time; obtaining a Doppler Power Spectrum of the acquired ultrasound signals; and determining the flow rate and/or the concentration of particles of the fluid by adjustment between, on the one hand, the obtained Doppler Power Spectrum and, on the other hand, a model of the Doppler Power Spectrum.
    Type: Application
    Filed: October 18, 2019
    Publication date: December 23, 2021
    Applicants: AENITIS TECHNOLOGIES, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ÉCOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Jean PROVOST, Jérémie GACHELIN, Baptiste PIALOT, Olivier COUTURE, Emmanuel VINCENT
  • Hepcidin antagonists for use in the treatment of inflammation
    Patent number: 11203753
    Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: December 21, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes, Université Paris Diderot—Paris 7
    Inventors: Carole Peyssonnaux, Jacques Mathieu, Sara Zumerle
  • TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
    Patent number: 11203788
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUD
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
    Patent number: 11203740
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventor: Nicole Brument
  • Ex vivo generation of ?? Foxp3regulatory T cells and therapeutic uses thereof
    Patent number: 11198851
    Abstract: The present invention relates to a method for ex vivo generating and expanding ?? Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR?? unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR?? unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR??+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo ?? Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR??+ Foxp3+.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 14, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERE MEDICALE), MEDECINE ET INNOVATION, UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
  • HOMEOPROTEINS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20210379144
    Abstract: The present disclosure relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 9, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE, SORBONNE UNIVERSITE
    Inventor: Alain Prochiantz
  • Lebecetin, a C-type lectin, as neovascularization inhibitor
    Patent number: 11191807
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 7, 2021
    Assignees: SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
    Inventors: Xavier Guillonneau, Fadoua Montassar, Naziha Marrakchi, Erij Messadi, Florian Sennlaub, José-Alain Sahel
  • Method of modulating epileptogenicity in a patient's brain
    Patent number: 11191476
    Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the model in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: December 7, 2021
    Assignees: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
  • Antibodies targeting tumor associated macrophages and uses thereof
    Patent number: 11186634
    Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud
    Inventors: Mary Poupot, Loïc Ysebaert, Marie Tosolini, Jean-Jacques Fournie, Pierre Brousset, Philippe Rochaix
  • Tourniquet with elastic sleeve
    Patent number: 11185337
    Abstract: The present invention relates to a tourniquet (1) comprising: • a support (2) for surrounding a first portion of a limb, • an elastic sleeve (4) to be held in a stretched position around the support (2), the support (2) preventing contraction of the elastic sleeve (4), • a grip element (8) which is movable relative to the support (2), • a drive element (6) for driving the elastic sleeve (4), when the grip element (8) is moved manually relative to the support (2), from its stretched position around the support to a blood vessel constricting position wherein the elastic sleeve (4) surrounds a second portion of the limb, adjacent to the first portion of the limb but not surrounded by the support (2), in such a way that the elastic sleeve (4) can contract by resilient return, and thus compress the second portion of the limb.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: November 30, 2021
    Assignees: SORBONNE UNIVERSITY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) FILIX
    Inventors: Guillaume Chenegros, Nicolas Libert, Stephane Carras
  • DIAGNOSIS METHOD OF MULTIPLE SCLEROSIS
    Publication number: 20210364533
    Abstract: A method for diagnosing or prognosing, multiple sclerosis including the steps of (a) measuring the amount of at least one first protein as set forth in SEQ ID NO: 1, the at least first protein belonging to the group of proteins: a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, (b) comparing the amount of the at least first protein with the amount of the same protein in a control sample, and (c) determining the status of the biological sample.
    Type: Application
    Filed: May 22, 2019
    Publication date: November 25, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE NÎMES
    Inventors: Eric THOUVENOT, Philippe MARIN, Serge URBACH, Geoffrey HINSINGER
  • Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
    Patent number: 11180510
    Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)—or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 23, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Stéphane Betzi, Sébastien Combes, Yves Collette, Laurent Hoffer, Xavier Morelli, Brigit Raux, Philippe Roche, Iuliia Voitovich
  • Capped and uncapped RNA molecules and block copolymers for intracellular delivery of RNA
    Patent number: 11179478
    Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Bruno Pitard
  • Device for acclimatising at altitude and method for functioning this device
    Patent number: 11179599
    Abstract: A device for acclimatising at altitude comprising a breathing mask defining a confined air space when it is placed on the face of a user. The mask comprising a suction valve to let the surrounding air enter inside the confined space when breathing in; an expiration valve to let air exit with a determined resistance, so as to create an overpressurisation of air in the confined space, when breathing out; and a sensor to establish information about the pressure of the confined space behind. The acclimatisation device in addition comprises a unit for processing the pressure information configured to establish a breathing characteristic of the user and compare it to at least one target value, in view of recommending to them an adjustment of the breathing mode thereof. A method for functioning this device is also provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: November 23, 2021
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE, UNIVERSITE DE CHAMBERY-UNIVERSITE SAVOIE MONT BLANC
    Inventors: Samuel Verges, Bernard Wuyam, Thomas Rupp